TIE2 Antibody (YA6798)

TIE2 Antibody (YA6798) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TIE2.

Predicted band size: 126 kDa;

Q02763

7010 [NCBI]

Shipping with blue ice.

Function：Tyrosine-protein kinase that acts as a cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of pro-inflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1

Subcellular Localization：Cell membrane,Cell junction,Cell junction, focal adhesion,Cytoplasm, cytoskeleton,Secreted

Expression：
Tissue_Specificity: Detected in umbilical vein endothelial cells. Proteolytic processing gives rise to a soluble extracellular domain that is detected in blood plasma (at protein level). Predominantly expressed in endothelial cells and their progenitors, the angioblasts. Has been directly found in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney

Isoforms & Post-Translational Modification：Q02763 has three isomers: Q02763-1: 125830 Da (predicted); Q02763-2: 121048 Da (predicted); Q02763-3: 109141 Da (predicted).
Proteolytic processing leads to the shedding of the extracellular domain (soluble TIE-2 alias sTIE-2)丨Autophosphorylated on tyrosine residues in response to ligand binding丨Ubiquitinated

Subunit：Homodimer

Angiopoietin 1 receptor antibody; Angiopoietin-1 receptor antibody; CD202b antibody; CD202b antigen antibody; Endothelial tyrosine kinase antibody; Endothelium specific receptor tyrosine kinase 2 antibody; hTIE 2 antibody; hTIE2 antibody; Hyk antibody; p140 TEK antibody; Angiopoietin 1 receptor antibody; Angiopoietin-1 receptor antibody; CD202b antibody; CD202b antigen antibody; Endothelial tyrosine kinase antibody; Endothelium specific receptor tyrosine kinase 2 antibody; hTIE 2 antibody; hTIE2 antibody; Hyk antibody; p140 TEK antibody; Soluble TIE2 variant 1 antibody; Soluble TIE2 variant 2 antibody; Tek antibody; tek tyrosine kinase antibody; TEK tyrosine kinase endothelial antibody; tek tyrosine kinase, endothelial antibody; TIE 2 antibody; TIE2 antibody; TIE2_HUMAN antibody; Tunica interna endothelial cell kinase antibody; Tyrosine kinase with Ig and EGF homology domains 2 antibody; Tyrosine kinase with Ig and EGF homology domains-2 antibody; Tyrosine protein kinase receptor TEK antibody; Tyrosine protein kinase receptor TIE 2 antibody; Tyrosine-protein kinase receptor TEK antibody; Tyrosine-protein kinase receptor TIE-2 antibody; Venous malformations multiple cutaneous and mucosal antibody; VMCM 1 antibody; VMCM antibody; VMCM1 antibody;